News : collaboration

View:
 

Found press releases

 

MOBERG DERMA TERMINATES COLLABORATION IN CANADA

12/22/2011 9:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (STO: MOB) and Medical Futures Inc. have agreed that the distribution agreement between the parties shall cease, and that cooperation ends. The agreement gave the distributor the exclusive right to market and sell Emtrix® in Canada.
Moberg Derma regains all rights to Emtrix® in Canada. The distributor has the right to sell off its stock for a period.

“Sales in Canada have not met expectations...

MOBERG DERMA AND MENARINI GROUP SIGN AGREEMENT FOR EMTRIX IN ITALY

12/9/2011 2:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (STO: MOB) has entered into a distribution agreement with Menarini Group for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Menarini’s OTC Division is granted exclusive rights to market and sell Emtrix® in Italy under the trademark YouDerm Emtrix®.
“The agreement is part of our international commercialization of Emtrix®. As...

MOBERG DERMA AND MEDA EXTEND LICENSE AGREEMENT

11/30/2011 8:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (publ.) and Meda have entered into an additional license agreement for Nalox™ - Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. The agreement extends Meda's rights to market and sell Nalox™ to Russia, Turkey and several countries in Eastern Europe. Moberg Derma assumes production and supply responsibility.

MOBERG DERMA AND MEDA SIGN AGREEMENT FOR NALOX IN EUROPE

9/19/2011 2:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (OMX: MOB) and Meda AB have entered into a license agreement covering rights for Nalox® - Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Meda is granted exclusive rights to market and sell Nalox® in a large number of countries in Europe. Moberg Derma assumes production and supply...

MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT IN AUSTRALIA AND NEW ZEELAND

6/8/2011 2:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (publ.) has entered into a distribution agreement with OzHealth Pharma for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement OZ Pharma Health is granted exclusive rights to market and sell Emtrix® in Australia and New Zeeland.
”The agreement is part of our international commercialization of Emtrix®, which now will be marketed...

MOBERG DERMA SIGNS DISTRIBUTION AGREEMENTS IN SPAIN AND UK

3/15/2011 4:40 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (publ) has entered into distribution agreements with AG Farma S.A. in Spain and HairXpertise Ltd in UK for Emtrix® – for treatment of discolored and deformed nails resulting from fungal infection (onychomycosis) or psoriasis. Under the agreements, the distributors are granted exclusive rights to market and sell Emtrix®.
”The agreements follow on a positive response in the Nordic market. Already...

MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT IN SWITZERLAND

12/3/2010 10:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (publ.) has entered into a distribution agreement with Gebro Pharma AG S.A. for Emtrix® – for treatment of discolored and deformed nails resulting from fungal infection  (onychomycosis) or psoriasis, and Kaprolac® – for problems with dry and flaky skin and. Under the agreement, Gebro is granted exclusive rights to market and sell Emtrix®, Kaprolac® Dandruff Shampoo and Kaprolac® Scalp Solution in...

MOBERG DERMA SIGNS AGREEMENT FOR EMTRIX® IN PORTUGAL AND 10 MARKETS IN AFRICA AN...

11/11/2010 3:30 AM EST  -   MOBERG DERMA AB
Moberg Derma AB today announced that a distribution agreement has been entered into with Laboratorio EDOL Produtos Farmaceuticos S.A. for Emtrix® – Moberg Derma’s product for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement EDOL is granted exclusive rights to market and sell Emtrix® in Portugal and ten markets in Africa and Central America. Moberg Derma will...

Antula launches Nalox™ in the Nordic region– Pharmacies report major demand for ...

9/14/2010 3:00 AM EST  -   MOBERG DERMA AB
Moberg Derma’s market partner in the Nordic countries – Antula Healthcare, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals – has now launched sales of Nalox™ in the Nordic region. Pharmacies have displayed great interest in Moberg Derma’s product Nalox™ – a treatment for discoloured and damaged nails caused by nail fungus or nail psoriasis.

MOBERG DERMA AND MEDICAL FUTURES INC SIGNS COMMERCIAL AGREEMENT FOR NAIL PRODUCT...

4/21/2010 3:35 AM EST  -   MOBERG DERMA AB
Moberg Derma AB, Sweden and Medical Futures Inc, Canada (“MFI”), today announced a commercial license agreement. The license covers distribution in Canada for Moberg Derma’s novel topical nail product – a treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Moberg Derma assumes supply responsibility, while MFI will be responsible for promotion in the...